Premier Perspectives Blog

Insider Insights in Clinical Development

Virtual Reality’s mainstream use in clinical research is no longer a fantasy. At the recent National Institutes of Health (NIH) Research Festival in America’s capital, attending clinical researchers were encouraged to strap on head-mounted virtual reality (VR) devices and image how they might enhance their clinical and basic research. The NIH even showcased its VirtualRead more

When it comes to clinical trials for neurodegenerative disease (NDD), it’s easy to get overwhelmed by complexity. Not only are the mechanisms that underlie NDDs like multiple sclerosis and Alzheimer’s still largely a mystery, their inherent variability is hard to account for. The best way to combat the problem? Break trial design down into more manageable pieces.Read more

It would be hard to overstate the need for new therapies that target unmet medical needs, especially in rare disease. After all, there are only about 400 approved “orphan drugs,” meaning that 95 percent of rare diseases lack a single approved treatment. Now the good news: U.S. and European regulators, recognizing the size and severityRead more

Last week, I attended World Orphan Drug Congress in Belgium. It was my first WODC, and it was a productive three days in Brussels – even if it was held at the airport hotel, and we never left the building! The congress agenda covered a wide range of topics in the rare and orphan diseaseRead more

As it was starting to get cold in the Northeast, a group of us snowbirded down to warm Florida for the CNS Summit. Before the conference began, we participated in STARR Coalition’s annual meeting. STARR Coalition is a remarkable group whose mission is to create meaningful change by increasing communication, partnerships, and goodwill among stakeholdersRead more

Today’s Tales from the Road comes from Corporate Recruiter, Raiza Rivera, who attended Come Tech Out the Triangle earlier this month. We exhibited at this tech-focused job fair in hopes of recruiting for several open technology positions at Premier.   “I came to the job fair today because I saw that Premier Research was on theRead more

Britain’s plans to leave the European Union could profoundly affect clinical drug research in the U.K. The impact spans a broad range of unknowns, from where the London-based EMA will put down roots to Brexit’s influence on trial regulations, cost, funding, and recruiting of scientific talent. Our Chief Medical Officer, Dr. Colin Hayward, addressed theseRead more

Rare disease is one of our main areas of focus here at Premier, so you’ll often see my colleagues and me talking about rare, through our webinars and white papers, and basically, almost any phone conversation with us. Last week, I attended the NORD Summit in Arlington, VA, and as usual, I found myself inspiredRead more

This week, we get a Tales from the Road two-for-one, from Dr. Colin Hayward, our Chief Medical Officer, who went to the Oxford Biotech Network Awards one week, and the ESMO Conference the next. Have a look: OBN Premier Research had the opportunity once again to support the Oxford Biotech Network (OBN) awards night. ThatRead more

Rising addiction rates are adding to already huge unmet needs in treating drug dependence, but big pharmaceutical companies show little interest in developing medications for common dependencies such as cannabis and methamphetamine. This volatile environment begs for trailblazers who can fill the void, but inconsistent patient behavior, lack of clear regulatory pathways, and other factorsRead more

Introducing Tales from the Road, a series of blogshorts, where our Premier People report in from their travels outside the office. Because sometimes, not everything that happens on the road stays on the road! Today’s inaugural post comes from Juliet Moritz, Executive Director, Strategic Development Department, Rare Diseases, reporting back on her trip to Amsterdam lastRead more

Over the course of more than 20 years in clinical research, I’ve sat in on more study budget development and negotiations meetings than I can count. What I’ve learned from those many thousands of hours of discussion is, whether you’re working with a global pharma company or a biotech start-up, the ultimate success of aRead more

Phone Us Now
Email Us Now